Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Nexium Could See Formulary Benefit From Prilosec OTC, AstraZeneca Says

  • News

Executive Summary

AstraZeneca Nexium sales could benefit from Prilosec OTC's effect on formulary coverage for proton pump inhibitors, CFO Jonathan Symonds said during an Oct. 23 quarterly earnings call

You may also be interested in...



Big Pharma’s “Black Wednesday”: Quarterly Reports Underscore Uncertainty

An unprecedented string of poor third-quarter earnings reports from the top pharmaceutical companies illustrates the importance of the Medicare debate to the future of the drug industry

Big Pharma’s “Black Wednesday”: Quarterly Reports Underscore Uncertainty

An unprecedented string of poor third-quarter earnings reports from the top pharmaceutical companies illustrates the importance of the Medicare debate to the future of the drug industry

PPI Coverage Adjusts To Prilosec OTC; Wyeth Sees Growth For Protonix In ‘04

Wyeth expects Protonix (pantoprazole) to remain a readily available "tier 2" agent in most health plans during 2004 despite the changing dynamics in the proton pump inhibitor market

Table

View full table

Tags:
Latest Headlines

CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings

Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds

Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing

Global Pharma Guidance Tracker – March 2024

See All
UsernamePublicRestriction

Register

PS042706

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By